Compare · CJJD vs YI
CJJD vs YI
Side-by-side comparison of China Jo-Jo Drugstores Inc. (CJJD) and 111 Inc. (YI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CJJD and YI operate in Retail-Drug Stores and Proprietary Stores (Consumer Staples), so they compete in similar markets.
- YI is the larger of the two at $47.9M, about 3.6x CJJD ($13.4M).
- YI has hit the wire 7 times in the past 4 weeks while CJJD has been quiet.
- Company
- China Jo-Jo Drugstores Inc.
- 111 Inc.
- Price
- $1.53+6.25%
- $5.47+1.11%
- Market cap
- $13.4M
- $47.9M
- 1M return
- -
- -20.15%
- 1Y return
- -
- -25.68%
- Industry
- Retail-Drug Stores and Proprietary Stores
- Retail-Drug Stores and Proprietary Stores
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 0
China Jo-Jo Drugstores Inc.
China Jo-Jo Drugstores, Inc., together with its subsidiaries, operates as a retailer and distributor of pharmaceutical and other healthcare products in the People's Republic of China. The company operates through four segments: Retail Drugstores, Online Pharmacy, Drug Wholesale, and Herb Farming. Its stores provide various pharmaceutical products, including prescription and over-the-counter drugs, nutritional supplements, traditional Chinese medicines (TCM), personal and family care products, and medical devices, as well as convenience products, such as consumable, seasonal, and promotional items. The company also operates licensed doctors of Western medicine and TCM on site for consultation, examination, and treatment of common ailments at scheduled hours. In addition, it operates dada360.com, an online drugstore that retails OTC drugs and nutritional supplements, as well as sells products through third-party platforms, such as Tmall, JD.com, and Amazon.com. Further, the company distributes third-party pharmaceutical products primarily to trading companies, as well as cultivates and wholesales herbs used for TCM. As of March 31, 2020, it had 118 retail pharmacies under the Jiuzhou Grand Pharmacy name, as well as 10 drugstores. The company was founded in 2003 and is headquartered in Hangzhou, the People's Republic of China.
111 Inc.
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2020, it operated 13 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Wuhan, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has strategic partnerships with Bayer Healthcare Co. Ltd.; BeiGene, Ltd.; and Jianming Pharmaceutical Group. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Latest CJJD
- Ridgetech, Inc. Announces 1-for-150 Reverse Share Split
- Amendment: SEC Form SCHEDULE 13D/A filed by China Jo-Jo Drugstores Inc.
- SEC Form 6-K filed by China Jo-Jo Drugstores Inc.
- SEC Form 6-K filed by China Jo-Jo Drugstores Inc.
- China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth
- SEC Form 6-K filed by China Jo-Jo Drugstores Inc.
- Amendment: SEC Form SC 13D/A filed by China Jo-Jo Drugstores Inc.
- SEC Form 6-K filed by China Jo-Jo Drugstores Inc.
- SEC Form 6-K filed by China Jo-Jo Drugstores Inc.
- Amendment: SEC Form SC 13D/A filed by China Jo-Jo Drugstores Inc.
Latest YI
- Director Luo Jun Justin was granted 810,271 units of RSUs and sold $25,516 worth of RSUs (99,720 units at $0.26) (SEC Form 4) to cover taxes
- Director Sun Jian David was granted 810,271 units of RSUs and sold $25,516 worth of RSUs (99,720 units at $0.26) (SEC Form 4) to satisfy withholding obligation
- Director Chen Yang Luke was granted 594,222 units of RSUs and sold $1,239 worth of RSUs (4,840 units at $0.26) (SEC Form 4) to satisfy withholding tax
- Director Teo Nee Chuan gave a grant of 811,889 units of RSUs, increasing direct ownership by 1,931% to 811,889 units (SEC Form 4)
- Director Chen Yang Luke gave a grant of 594,222 units of RSUs, increasing direct ownership by 135% to 594,222 units (SEC Form 4)
- Director Luo Jun Justin gave a grant of 810,271 units of RSUs, increasing direct ownership by 2,106% to 810,271 units (SEC Form 4)
- Director Sun Jian David gave a grant of 810,271 units of RSUs, increasing direct ownership by 2,106% to 810,271 units (SEC Form 4)
- SEC Form 20-F filed by 111 Inc.
- SEC Form 6-K filed by 111 Inc.
- 111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results